多西他赛联合雷替曲塞二线治疗晚期胃癌临床观察

clinical observation on the treatment of advanced gastric cancer by second-line treatment with combination of docetaxel and raltitrexed

目的探讨多西他赛联合雷替曲塞二线治疗晚期胃癌的近期疗效及不良反应。方法一线化疗失败或一线化疗病情缓解后再进展的晚期胃癌患者42例,采用多西他赛联合雷替曲塞方案二线化疗,2个周期后评价疗效,并观察化疗不良反应。结果本组CR 0例,PR 9例(21.4%),SD 17例(40.5%),PD16例(38.1%),ORR 21.4%,DCR为61.9%。主要的不良反应为血液毒性、恶心呕吐、疲劳及转氨酶升高,多为Ⅰ~Ⅱ度,对症处理后能好转,未出现明显过敏反应。结论多西他赛联合雷替曲塞二线治疗晚期胃癌仍有一定的疗效,且不良反应可耐受,可选择作为晚期胃癌二线化疗方案。

Objective To explore the recent effects and adverse reactions on the treatment of advanced gastric cancer by second-line treatment with combination of docetaxel and rahitrexed. Methods 42 patients with advanced gastric cancer after the failure of first-line chemotherapy or first-line chemotherapy were given second-line treatment with combination of docetaxel and raltitrexed. After 2 cycles, the efficacy and adverse effects of chemotherapy were evaluated. Results In this group, CR was 0 cases, PR was 9 cases （21.4%）, SD was 17 cases （40.5%）, PD was 16 （38.1%）, ORR was 21.4% and DCR was 61.9%. The main adverse reactions were blood toxicity, nausea, vomiting, fatigue and transaminase eleations, mostly Ⅰ - Ⅱ degrees. All adverse reactions were reversed by symptomatic treatment, there was no obvious allergic reaction. Conclusion There is still a certain curative effect in the treatment of advanced gastric cancer by the combination of docetaxel and rahitrexed, which can be tolerated and can be selected as second-line chemotherapy for advanced gastric cancer.